Back to Agenda
Experimental Studies: New Approaches to Study Designs to Facilitate Early Phase Decision Making
Session Chair(s)
Adam F Cohen, MD, PharmD, FACC, FFPM
Chief Eecutive Officer
Centre for Human Drug Research, Netherlands
This session will follow the life of a biomarker from the nonclinical arena to its use in clinical trials. The characteristics of a useful biomarker will be discussed. Examples of protocol designs and statistical analysis approaches that use mechanism of action at the molecular level to inform go/no-go decisions will be discussed.
Learning Objective : Describe the characteristics of a useful biomarker; Illustrate examples of protocol designs and statistical analysis approaches at the molecular level.
Speaker(s)
Experimental Studies
Adam F Cohen, MD, PharmD, FACC, FFPM
Centre for Human Drug Research, Netherlands
Chief Eecutive Officer
![Gengqian Cai, DrSc](/_Images/member/Generic_Image_Missing-Profile.jpg)
Quantitative Approaches to Design and Analysis of Experimental Medicine Clinical Trials
Gengqian Cai, DrSc
GlaxoSmithKline, United States
Director, Statistics and Programming
Have an account?